Sign in
Active, not recruitingPhase 1

Study to Evaluate Investigational Allogeneic Cell Therapy Product hOMSC300 for Treatment of Early to Moderate Stage Multiple System Atrophy (MSA)

Key facts

Who runs it
Cytora Ltd.
Where
Israel1 site in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
Phase
Phase 1
People taking part
10 people enrolled
Started
7 Nov 2022
Ended
19 Feb 2026
Type of study
Interventional, 2 groups
Treatments tested
  • hOMSC300
Record updated
29 January 2025

Who can take part

Age
50 years to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Patient was diagnosed with probable MSA-C (cerebellar) or MSA-P (parkinsonian) variant within 60 months of symptom onset (excluding impotence)
  • Subject can ambulate without the assistance of another person, defined as the ability to take at least 10 steps. Use of assistive devices is allowed
  • Patient cognitive state permits him to sign informed consent, according to the PI's clinical judgement, and MoCA >= 24

Who cannot take part

  • Participants with a clinically significant or unstable medical or surgical condition that, in the opinion of the investigator, might preclude safe completion of the treatment or affect the treatment outcome
  • Patients with thrombocytopenia, other bleeding diathesis or taking anticoagulant therapy (not including Aspirin up to 100mg per day)
  • Patients with known hypersensitivities to Plasmalyte, Gadolinium, Penicillin, and with general hypersensitivity to antibiotics
  • Patients who fulfill the criteria of Parkinson's Disease
  • History of electroconvulsive therapy
  • History of brain surgery
  • Pregnant women and women before menopause

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Purpose of this phase 1 study is to assess the safety of intrathecal administration of allogeneic human oral mucosa stem cells (hOMSCs) in patients suffering from early to moderate stage Multiple System Atrophy (MSA)

The 2 groups in the trial

  • Low dose hOMSC300Treatment being tested

    Single IT administration of low dose hOMSC300

    Treatment: hOMSC300

  • High dose hOMSC300Treatment being tested

    Single IT administration of high dose hOMSC300

    Treatment: hOMSC300

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Phase 1 Open-Label Study for Treatment of Early to Moderate Stage Multiple System Atrophy Patients With the Investigational Allogeneic Cell Therapy Product, hOMSC300
Record updated
29 January 2025